Ampio Pharmaceuticals Inc  

(Public, NYSEMKT:AMPE)   Watch this stock  
Find more results for K. Giles
+0.03 (1.58%)
Real-time:   3:38PM EST
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.81 - 1.93
52 week 1.69 - 9.01
Open 1.86
Vol / Avg. 105,093.00/226,267.00
Mkt cap 98.80M
P/E     -
Div/yield     -
EPS -0.61
Shares 52.00M
Beta 0.77
Inst. own 24%
Nov 19, 2015
Ampio Pharmaceuticals Inc Conference Call to discuss its Aytu BioScience Common Stock Distribution
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1597.62% -50851.38%
Operating margin -1574.14% -50880.36%
EBITD margin - -50308.54%
Return on average assets -54.32% -73.48%
Return on average equity -61.38% -76.87%
Employees 23 -
CDP Score - -


373 Inverness Pkwy Ste 200
ENGLEWOOD, CO 80112-5898
United States - Map
+1-720-4376500 (Phone)
+1-720-4376501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. The Company is also focused on developing and monetizing its Oxidation Reduction Potential (ORP) diagnostic device and sexual dysfunction portfolio. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA) for the treatment of osteoarthritis and other inflammatory conditions. Optina is a low-dose formulation of danazol for the treatment of diabetic macular edema (DME). The Company's subsidiaries include Luoxis Diagnostics, Inc. (Luoxis), an in-vitro diagnostics company, and Vyrix Pharmaceuticals, Inc. (Vyrix), a specialty pharmaceutical company.

Officers and directors

Michael Macaluso Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Gregory A. Gould CPA Chief Financial Officer, Treasurer, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
David Bar-Or M.D. Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
Vaughan Lennox Clift M.D. Chief Regulatory Affairs Officer
Age: 53
Bio & Compensation  - Reuters
Philip H. Coelho Independent Director
Age: 71
Bio & Compensation  - Reuters
Richard B. Giles Independent Director
Age: 65
Bio & Compensation  - Reuters
David R. Stevens Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters